北米てんかん市場予測 2030年 - 地域別分析 - タイプ別(進行性ミオクロニーてんかん、反射性てんかん、全般てんかん、その他)、投与経路別(経口、非経口、その他)、治療タイプ別(第1世代医薬品、第2世代医薬品、第3世代医薬品)、年齢層別(成人および小児)、流通チャネル別(病院薬局、小売薬局、その他)

BMIRE00030781 | Pages: 135 | Pharmaceuticals | Sep 2024 | Type: Regional | Status: Published
北米のてんかん市場は、2022年に25億7,710万米ドルと評価され、2030年までに36億934万米ドルに達すると予想されています。また、2022年から2030年にかけて4.3%のCAGRを記録すると推定されています。

てんかんの罹患率の上昇が北米のてんかん市場を活性化

てんかんは発作性疾患とも呼ばれ、脳の慢性疾患です。特徴は、身体の一部または全体の不随意運動の短いエピソードである再発性発作です。発作により、感覚、行動、意識、筋肉の動きが変化することがあります。てんかんは、遺伝性疾患または外傷や脳卒中などの後天性脳損傷が原因で発生する場合があります。世界保健機関(WHO)が2023年2月に発表したデータによると、てんかんは世界の疾病負担のかなりの部分を占めており、世界中で約5,000万人が罹患しています。さらに、1,000人中4~10人が活動性てんかん(治療が必要な状態、または発作が続く状態)を患っていると推定されています。毎年約500万人がてんかんと診断されています。高所得国では、年間10万人中49人の割合でてんかんが報告されていると推定されています。この数は、低所得国と中所得国では10万人中139人に達することもあります。てんかん発症率の上昇は、交通事故や出産関連の負傷の増加、神経嚢虫症やマラリアなどの風土病のリスクの上昇に起因すると考えられます。 WHO はまた、てんかん患者の約 70% は薬物の使用により発作を起こさなくなると述べています。てんかんを抑制する治療法には、抗てんかん薬、特別な食事療法 (抗てんかん薬に加えて)、手術などがありますが、抗てんかん薬療法はほとんどの患者に処方される主な治療法です。したがって、世界中でてんかんの罹患率が上昇していることが市場の成長を牽引しています。

北米てんかん市場の概要

北米てんかん市場は、米国、カナダ、メキシコに分かれています。この地域の市場成長は、てんかん患者数の増加、高齢化人口の増加、この地域でのてんかん薬分野の継続的な研究開発、新製品の規制承認の増加、てんかん薬による事故や脳損傷の増加に起因しています。

北米てんかん市場の収益と2030年までの予測(百万米ドル)

北米てんかん市場のセグメンテーション

北米てんかん市場は、タイプ、投与経路、治療タイプ、年齢層、流通チャネル、および国に分類されています。

タイプに基づいて、北米てんかん市場は、進行性ミオクロニーてんかん、反射てんかん、全般てんかん、その他に分類されます。全般てんかんセグメントは、2022年に最大の市場シェアを占めました。

投与経路の面では、北米てんかん市場は、経口、非経口、その他に分類されます。経口セグメントは、2022年に最大の市場シェアを占めました。

治療タイプ別に、北米てんかん市場は、第1世代の薬、第2世代の薬、第3世代の薬に分類されます。 2022年には、第3世代医薬品セグメントが最大の市場シェアを占めました。

年齢層に基づいて、北米のてんかん市場は成人と小児に分かれています。成人セグメントは2022年に大きな市場シェアを占めました。

流通チャネルの観点から、北米のてんかん市場は、病院薬局、小売薬局、その他に分類されています。病院薬局セグメントは2022年に最大の市場シェアを占めました。

国別に見ると、北米のてんかん市場は米国、カナダ、メキシコに分かれています。2022年には、米国が北米のてんかん市場シェアを独占しました。

アボットラボラトリーズ、ファイザー社、エーザイ株式会社、UCB SA、リバノバ社、ノバルティスAG、メドトロニック社、GSK社、H.ルンドベック社は、北米てんかん市場で事業を展開している大手企業の一部です。

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches

4.1.1 Cell and Gene Therapy Approaches

4.1.2 Encapsulated cell bio delivery (ECB) system

4.1.3 Gene Therapy for Epilepsy Clinical Overview

4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy

4.1.3.1.1 Gene Supplementation - Overview

4.1.3.1.2 Gene Modulation - Overview

4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview

4.1.3.1.4 Neuropeptides - Overview

4.1.3.1.5 Engineered Channels - Overview

4.1.3.1.6 Endogenous Channels - Overview

4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy

4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy

4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy

4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy

4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview

4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches

4.1.3.6 Potassium Channels for Human Epileptic Phenotypes

4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. North America Epilepsy Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Epilepsy

5.1.2 Increasing Investments in Development of Epilepsy Therapies

5.2 Market Restraints

5.2.1 Recall of Products

5.3 Market Opportunities

5.3.1 Surge in Awareness Programs Conducted by Organizations

5.4 Future Trends

5.4.1 Gene Therapy as Promising Treatment Approach

5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - North America Analysis

6.1 North America: Epilepsy Market Overview

7. North America Epilepsy Market Analysis - by Type

7.1 Overview

7.2 Progressive Myoclonic Epilepsy

7.2.1 Overview

7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Reflex Epilepsy

7.3.1 Overview

7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Generalized Epilepsy

7.4.1 Overview

7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Other

7.5.1 Overview

7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Epilepsy Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Others

8.4.1 Overview

8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Epilepsy Market Analysis - by Treatment Type

9.1 Overview

9.2 First Generation Drugs

9.2.1 Overview

9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Second Generation Drugs

9.3.1 Overview

9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Third Generation Drugs

9.4.1 Overview

9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Epilepsy Market Analysis - by Age Group

10.1 Overview

10.2 Adult

10.2.1 Overview

10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10.3 Children

10.3.1 Overview

10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Epilepsy Market Analysis - by Distribution Channel

11.1 Overview

11.2 Hospital Pharmacies

11.2.1 Overview

11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.3 Retail Pharmacies

11.3.1 Overview

11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.4 Others

11.4.1 Overview

11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. North America Epilepsy Market - Country Analysis

12.1 North America Epilepsy Market Overview

12.1.1 North America: Epilepsy Market Breakdown- by Country, 2022 and 2030 (%)

12.1.1.1.1 United States: Epilepsy Market Overview

12.1.1.1.2 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.1.3 United States: Epilepsy Market Breakdown, by Type

12.1.1.1.4 United States: Epilepsy Market Breakdown, by Route of Administration

12.1.1.1.5 United States: Epilepsy Market Breakdown, by Treatment Type

12.1.1.1.6 United States: Epilepsy Market Breakdown, by Age Group

12.1.1.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.1.8 Canada: Epilepsy Market Overview

12.1.1.1.9 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.1.10 Canada: Epilepsy Market Breakdown, by Type

12.1.1.1.11 Canada: Epilepsy Market Breakdown, by Route of Administration

12.1.1.1.12 Canada: Epilepsy Market Breakdown, by Treatment Type

12.1.1.1.13 Canada: Epilepsy Market Breakdown, by Age Group

12.1.1.1.14 Canada: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.1.15 Mexico: Epilepsy Market Overview

12.1.1.2 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.2.1 Mexico: Epilepsy Market Breakdown, by Type

12.1.1.2.2 Mexico: Epilepsy Market Breakdown, by Route of Administration

12.1.1.2.3 Mexico: Epilepsy Market Breakdown, by Treatment Type

12.1.1.2.4 Mexico: Epilepsy Market Breakdown, by Age Group

12.1.1.2.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview

13.2 Growth Strategies in Epilepsy Market

13.3 Organic Growth Strategies

13.3.1 Overview

13.4 Inorganic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Pfizer Inc

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Eisai Co Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 UCB SA

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 LivaNova Plc

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Medtronic Plc

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 GSK Plc

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 H. Lundbeck AS

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

 

 

List of Tables

Table 1. North America Epilepsy Market Segmentation

Table 2. Cell Therapy Approach - An Overview

Table 3. Gene Therapy Approach - An Overview

Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview

Table 5. Preclinically Tested Genetic Therapies for Epilepsy

Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview

Table 7. Viral Vectors Comparison with respect to Various Parameters

Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies

Table 9. Enzyme-Inducing Antiepileptic Drugs

Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview

Table 11. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 12. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 13. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type

Table 14. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group

Table 15. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 16. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 17. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 18. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type

Table 19. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group

Table 20. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 21. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 22. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 23. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type

Table 24. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group

Table 25. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 26. Recent Organic Growth Strategies in Epilepsy Market

Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market

?

List of Figures

Figure 1. North America Epilepsy Market Segmentation, by Country

Figure 2. Epilepsy Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030

Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)

Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)

Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)

Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)

Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. North America: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)

Figure 26. North America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 28. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 29. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 30. Growth Strategies in Epilepsy Market

 

 

?

  1. Abbott Laboratories
  2. Pfizer Inc
  3. Eisai Co Ltd
  4. UCB SA
  5. LivaNova Plc
  6. Novartis AG
  7. Medtronic Plc
  8. GSK Plc
  9. H. Lundbeck AS
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America epilepsy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the North America epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America epilepsy market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440